# GATA2

Source: https://onco.cc/targets/gata2/  
OnCo record `gata2` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

GATA2 (Endothelial transcription factor GATA-2) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Myeloproliferative neoplasms, Myelodysplastic syndromes / neoplasms and 5 more.

## Summary

Transcriptional activator which regulates endothelin-1 gene expression in endothelial cells. Binds to the consensus sequence 5'-AGATAG-3'.

CIViC holds 2 clinical evidence items and 0 assertions across 2 variants, naming Bortezomib and Fasudil. Open Targets scores its association with cancer at 0.84 (direct and indirect evidence; datatypes genetic literature 0.89, literature 0.98, genetic association 0.82, somatic mutation 0.95, animal model 0.57). IntOGen calls it a driver in 5 cohorts (3 activating, 1 loss-of-function), covering Acute Myeloid Leukaemia, Head and Neck Squamous Cell Carcinoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: GATA binding protein 2; Endothelial transcription factor GATA-2; NFE1B
- Tags: cancer-genes-wave
- Symbol: GATA2
- Class: transcription
- Biology: Transcriptional activator which regulates endothelin-1 gene expression in endothelial cells. Binds to the consensus sequence 5'-AGATAG-3'. Location: Nucleus (UniProt). Locus 3q21.3 (HGNC).
- Where found: Leukaemia: Open Targets association 0.80 with leukaemia (MONDO_0005059); Myeloproliferative neoplasms: Open Targets association 0.80 with myeloproliferative neoplasm (MONDO_0020076); Myelodysplastic syndromes / neoplasms: Open Targets association 0.77 with myelodysplastic syndrome (MONDO_0018881); Prostate cancer: Open Targets association 0.57 with prostate cancer (MONDO_0008315); Head and neck squamous cell carcinoma: IntOGen driver in 1 cohort (HNSC); Skin cancer: Open Targets association 0.54 with skin cancer (MONDO_0002898)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 2 therapies; IntOGen calls it an activating (Act) driver in 3 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; CIViC holds 2 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:4171: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4171
- UniProt P23769: https://www.uniprot.org/uniprotkb/P23769/entry
- NCBI Gene 2624: https://www.ncbi.nlm.nih.gov/gene/2624
- Ensembl ENSG00000179348: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000179348

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/), [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/), [Prostate cancer](https://onco.cc/cancers/prostate/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)

---
JSON: https://onco.cc/api/v1/entities/gata2.json